

PIAS2 RABBIT PAB

货号: S214096

产品全名: PIAS2 兔多抗

基因符号: DIP; MIZ; MIZ1; SIZ2; ARIP3; PIASX; ZMIZ4; PIASX-BETA; PIASX-ALPHA

UNIPROT ID: O75928 (Gene Accession - NP_004662)

背景: This gene encodes a member of the protein inhibitor of activated STAT (PIAS) family. PIAS proteins function as SUMO E3 ligases and play important roles in many cellular processes by mediating the sumoylation of target proteins. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. Isoforms of the encoded protein enhance the sumoylation of specific target proteins including the p53 tumor suppressor protein, c-Jun, and the androgen receptor. A pseudogene of this gene is located on the short arm of chromosome 4. The symbol MIZ1 has also been associated with ZBTB17 which is a different gene located on chromosome 1.

抗原: Synthetic peptide of human PIAS2

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 1000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling, Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 214096(PIAS2 Antibody) at a dilution of 1/70(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the synthetic peptide and then with 214096(Anti-PIAS2 Antibody) at dilution 1/70.



The image on the left is immunohistochemistry of paraffin-embedded Human Lymphoma tissue using 214096(Anti-PIAS2 Antibody) at a dilution of 1/70.



In comparison with the IHC on the left, the same paraffin-embedded Human lymphoma tissue is first treated with synthetic peptide and then with D161334(Anti-PIAS2 Antibody) at dilution 1/70.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
